CV of Bhrigu Kumar Das

Name: Dr. Bhrigu Kumar Das

Designation: Associate Professor

Address for communication: (office) Department of Pharmacology, School of Pharmaceutical Sciences, NH37, Azara, Guwahati-781017, Assam, India.

Mobile No.: +91-8011831765

WA No: +91-8011831765

Email: bhrigu_pharmag@gcuniversity.ac.in

Date of Birth: 31-08-1990

Educational Qualifications:

Sl. No.	Examination Passed	Year of passing	Board / Council / University	Specialization
1	HSLC/10th Std.	2006	SEBA, Guwahati	--
2	HSSLC/10+2 Std.	2008	AHSEC, Guwahati	--
3	Degree (B. Pharm)	2013	Gauhati University	Pharmacy
4	Master's Degree (M. Pharm in Pharmacology)	2015	KLE University, Karnataka	Pharmacology
6	Ph. D. (Pharmaceutical Science)	2022	KLE University, Karnataka	Pharmaceutical Science
7	Post-Doctoral (Please Specify)			
8	Others (PGDCR&PV)	2015	ICBio, CRO, Innovative Centre for Biosciences, Bangalore, India.	Clinical Research and Pharmacovigilance

Languages known: (Read, Write & Speak)

English, Assamese, Hindi.

Academic/ Administrative Experience:

1. Teaching experience (6.0 years).
2. Research experience (7.0 years).

List of Publications (Research/Review articles/Book Chapters):

1. Goswami, A.K., Sarma, A., Ahmed, S., **Das, B.K**. 2025. Linalool in chronic diseases: A comprehensive review of its pharmacological potential and delivery aspects. Fitoterapia, 106754. https://www.sciencedirect.com/science/article/abs/pii/S0367326X25003806 **[Impact Factor: 2.6].**
2. Mehta, P., Saha, D., Das, T., **Das, B.K.**, 2025. Targeting the gut microbiome dynamics and treatment strategies in acute pancreatitis. *Pharmacol. Res. Nat. Pro*., 8:100306. https://doi.org/10.1016/j.prenap.2025.100306
3. Chakraborty, J., Singh, N.L., **Das, B.K**., 2025. Gut microbiome and lung cancer: Mechanisms, interactions, and dietary interventions. *Gut Microbes Rep*. 2(1):1-40. https://www.tandfonline.com/doi/full/10.1080/29933935.2025.2501313
4. Mehta, P., Saha, D., Das, A., **Das, B.K.**, 2025. Gut microbiota in diabetic-linked polycystic ovarian syndrome: Mechanisms and therapeutic insights. *Tissue Cell*. 95:102870.https://www.sciencedirect.com/science/article/abs/pii/S0040816625001508?via%3Dihub **[Impact Factor: 2.7].**
5. Arandhara, A., Bhuyan, P., **Das, B.K.**, 2025. Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies. *Discov Oncol*. 16(1):159. https://link.springer.com/article/10.1007/s12672-025-01902-y **[Impact Factor: 2.8].**
6. Arandhara, A., Saha, D., **Das, B.K.**, 2025. Evaluation of the cardioprotective potential of hydroethanolic extract of *Koenigia polystachya* L. (Qiú xù liǎo) leaves against isoproterenol- induced myocardial infarction in rats. *Pharmacol. Res. Mod. Chin. Med*. 15:100612. https://doi.org/10.1016/j.prmcm.2025.100612
7. Sarma, A., Chakraborty, T., **Das, B.K.**, Goswami, A.K., 2025. Nano based enemas for colon targeting. In: *Nanocarriers Based Colon Targeting*, Chapter 22, pp. 601–629. Elsevier. https://www.sciencedirect.com/science/article/pii/B9780443248061000224
8. **Das, B.K.**, Sarma, A., Goswami, A.K., 2024. Gut-health pharmacology: Integrating microbiota insights with natural product-based therapies. Rudrapal M, Egbuna C, Cho

WC, editors. Biochem Mol Pharmacol Drug Dis. A volume in drug discovery update. Elsevier; p. 377-399. ISBN: 978-0-443-16013-4. https://www.sciencedirect.com/science/article/abs/pii/B978044316013400018X

9. Kashyap, A., Sarma, A., **Das, B.K.**, Goswami, A.K. 2024. Rational Design of Natural Products for Drug Discovery.Computational Methods for Rational Drug Design, p. 285-309. https://doi.org/10.1002/9781394249190.ch13
10. Sarma, S.K., Dutta, U., **Das, B.K.**, Bharali, A., Laloo, D., Kalita, J.M., Sahu, B.P., 2024. Evaluation of Lakadong turmeric derived curcumin nanogel against resistant biofilms: In-silico, antibacterial and antibiofilm analysis. J Appl Pharm Sci. 14(09):208–216. http://doi.org/10.7324/JAPS.2024.170144
11. Sultana, A., **Das, B.K.**, Saha, D. 2024. Role of Hentriacontane on Dexamethasone-induced insulin resistance in rats. Pharmacol. Res. Nat. Pro., 100063. https://doi.org/10.1016/j.prenap.2024.100063
12. Ghosh, N., James, R., Saha, D., **Das, B.K.** 2024. Phytochemicals as autophagy modulators in hepatocellular carcinoma. *Curr. Bioact. Compd*. https://www.eurekaselect.com/article/141277
13. Bora, S.J., Deka, D.J., Malakar, C., Kashyap, N., **Das, B.K.** 2024. Breast Cancer Management: The role of nutrition, exercise and psychosocial well-being. *Curr. Cancer Ther. Rev*., 20. https://doi.org/10.2174/0115733947286944240223101937 **[Impact Factor: 0.6]**
14. Chavda, V. P., Duo, Y., Bezbaruah, R., Kalita, T., Sarma, A., Deka, G., Duo, Y., **Das, B.K.**, Shah, Y., Postwala, H. 2024. Unveiling the promise: Exosomes as game-changers in anti-infective therapy. *Exploration*. https://doi.org/10.1002/exp.20230139
15. Sultana, A., Borgohain R., Rayaji A., Saha D., **Das, B.K.**, 2024. Promising phytoconstituents in diabetes-related wounds: Mechanistic insights and implications. *Curr. Diabetes Rev*. https://www.eurekaselect.com/article/138827 [**Impact Factor: 3.3**]
16. Arandhara, A., Saha, D., Deka, D.J., Deka, M., **Das, B.K.,** 2024. Redox imbalance and cardiovascular pathogenesis: Exploring the therapeutic potential of phytochemicals. *Curr. Bioact. Compd*. 20. https://doi.org/10.2174/0115734072279525231210144617.
17. Kiba, A., Saha, D., **Das, B.K.**, 2023. Exploration of the anti-diabetic potential of hydro-ethanolic leaf extract of *Koenigia polystachya* L.: An edible wild plant from Northeastern India. *Lab. Anim Res.* 39(1);21:1-10. [**Impact Factor: 2.9**]

18. Sarma M.K., Saha D., **Das B.K.**, Das T., Azizov S., Kumar D. 2023. A delve into the pharmacological targets and biological mechanisms of *Paederia foetida* Linn.: A rather invaluable traditional medicinal plant. *Naunyn Schmiedebergs Arch. Pharmacol*. **[Impact Factor: 3.6]**
19. Krishnatreyya H., Hazarika H., **Das B.K.**, Gogoi N., Ahmed A.B., 2023. Zaman K. Drug delivery options for treatment of ebola infection. *Viral Drug Delivery Systems: Advances in Treatment of Infectious Diseases*. 161-191. https://link.springer.com/chapter/10.1007/978-3-031-20537-8_8
20. **Das, B.K.**, 2022. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings. *APMIS*. [**Impact Factor: 3.428**]
21. **Das, B.K.**, K, Jayalakshmi, Gadad P.C., 2022. ^{1}H-NMR-based serum metabolomic study to evaluate the effect of asarone and metformin on experimentally induced diabetic hepatocellular carcinoma in rats. *Bull. National Res Centre*. 46:164.
22. **Das, B.K.**, Gadad P.C., 2021. Impact of diabetes on the increased risk of hepatic cancer: An updated review of biological aspects. *Diabetes Epidemiol Manag.* 4:100025.
23. **Das, B.K.**, Saha, D, Gadad, P.C., 2021. *In silico* discovery of novel phytoconstituents of *Diplazium esculentum* Retz. against diabetes mellitus. *Chemistry Africa*. 4:1-12. [**Impact Factor: 2.6**]
24. **Das, B.K.**, Knott, R.M., Gadad, P.C., 2021. Metformin and asarone inhibit HepG2 cell proliferation in a high glucose environment by regulating AMPK and Akt signaling pathway. *Futur. J. Pharm. Sci*., 7: 43. [**Impact Factor: 2.7**]
25. **Das, B.K.,** Gadad, P.C., 2020. Asarone and metformin modulates the oxidant-antioxidant imbalance on experimentally induced hepatocellular carcinoma during diabetic condition. *Indian J. Pharm. Educ. Res*., 54:1039-1045. [**Impact Factor: 0.843**]
26. **Das, B.K.,** Choukimath S.M., Gadad, P.C., 2019. Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu. *Life Sci*., 230:10-8. [**Impact Factor: 6.78**]
27. **Das, B.K.,** Swamy, A.H.M.V., Koti, B.C.,Gadad, P.C., 2019. Experimental evidence for use of *Acorus calamus* (asarone) for cancer chemoprevention. *Heliyon*. 5: e01585. [**Impact Factor: 4.0**]

28. Krishna, R.J., Pandagale, A., Ronad, P.M., Honnalli, S.S., **Das, B.K.,** Gadad, P.C., 2019. Synthesis and pharmacological evaluation of schiff bases of 7-amino-4-methyl coumarins as novel anti-inflammatory agents. *Asian J. Pharm. Pharmacol*., 5: 693-700.
29. **Das, B.K.,** Koti, B.C., Patil, S.B., Gadad, P.C., 2019. Effect of *Lycopersicon esculentum* (tomato) on membrane-bound ATPases against diethylnitrosamine (DEN) induced and phenobarbital (PB) promoted hepatocellular carcinoma (HCC) in rats. *Asian J. Pharm. Pharmacol*., 5: 565-571.
30. Singh, M.K., **Das, B.K.,** Choudhary, S., Gupta, D., Patil, U.K., 2018. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. *Biomed. Pharmacother*., 106: 991-1002. [**Impact Factor: 7.5**]
31. **Das, B.K.,** Koti, B.C., Gadad, P.C., 2016. Role of *Lycopersicon esculentum* in diethylnitrosamine-induced and phenobarbital-promoted hepatocellular carcinoma. *Indian J. Health Sci*., 9:147-52.
32. **Das, B.K.,** Kulkarni, J.M., 2016. The landscape of therapeutic cancer vaccine. *Int. J. Pharm. Sci. Res*.,7:514-519.
33. **Das, B.K.,** Singh, M.K., Kulkarni, J.M., 2016. Potential gastroprotective medicinal plants: An overview. *Int. Res. J. Pharm*., 7: 8-14.
34. Singh, M.K., **Das, B.K.**, Patidar, P., 2016. The effect of methanolic extract of *Buchanania lanzan* Spreng seeds on hematological indices. *Indian J. Pharmacol*., 48: 214-215. [**Impact Factor: 2.83**]
35. Singh, M.K., **Das, B.K.**, Trivedi, R., 2016. *In vivo* evaluation of immunomodulatory potential of ferulic acid. *Int. Res. J. Pharm*., 7: 12-17.
36. **Das, B.K.,** 2015. A brief scenario of Dengue virus. *Int. J. Curr. Res*., 7: 12864-12873.
37. **Das, B.K.,** 2014. An overview on Hirudotherapy/leech therapy. *Indian Res. J. Pharm. Sci*., 1:33-45.

Conference publications:

1. Kiba, A, Saha, D., **Das, B.K.,** NMPB (Ministry of AYUSH) Govt. of India Sponsored National Conference. Nagaon, Assam, India. Page no: 93, Jan, 2022.
2. Kamaiah, J., **Das, B.K.,** Gadad P.C., 24th Conference of National Magnetic Resonance Society. Department of Physics, IISER Mohali, Punjab, India. Page no: 66, Feb, 2018.

3. **Das, B.K.,** Koti, B.C., Swamy, A.H.M.V., Gadad P.C., World Congress on Drug Discovery Development. J N Tata Auditorium, Indian Institute of Science, Bengaluru. Page no: 1, Nov, 2016.

Research Experience:

- Research & Consultancy Projects:
    1. Received a grant of ₹ 1.10 Crore from the Department of Science and Technology-Fund for Improvement of S&T Infrastructure (DST-FIST) [SR/FST/COLLEGE-/2021/1172 (as a part of the Project Implementation Group (PIG)]-2022.

Membership of Professional bodies:

1. Lifetime membership of the Human Ethics Committees Association (HECA), Bangalore, Karnataka, India.

Award, Fellowship & Recognition:

1. Full-time Ph.D. Research Scholar grant (of contingency and scholarship) from KLE University, Belgaum, Karnataka (2016-2019).
2. Received a fellowship from the AICTE, Government of India (August 2013 to July 2015) for qualifying for the Graduate Pharmacy Aptitude Test (GPAT) conducted by All India Council for Technical Education (AICTE)-2013.

Scanned Signature

Date: 21.08.25 (Bhrigu Kumar Das)